Amgen packs up in Claudin6
Meanwhile, Torl BioTherapeutics appears to be catching up with BioNTech.
Meanwhile, Torl BioTherapeutics appears to be catching up with BioNTech.
The group abandons plans in lung cancer with Met exon 14 skipping, to focus on Met amplifications.
Earnings season begins again, while big readouts loom for ALX and Fibrogen.
The EU recommendation for odronextamab comes after a US rejection in March.
Merck and Daiichi’s first ADC attempt is knocked back, while Geron gets its inaugural approval.
A complete response letter for Merck & Co and Daiichi’s patritumab deruxtecan might not be fatal, but it’s certainly embarrassing.
Meanwhile, Bristol’s other competition in this disease looks set to come from China.
A mysterious ASCO poster, patient deaths and now clinical hold; where next for BioNTech’s ADC deal?
Imfinzi scores an unexpected approval based on a post-hoc subgroup analysis.